You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Claims for Patent: 11,129,833

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,129,833

Title:	Methotrexate formulation
Abstract:	A liquid pharmaceutical composition comprises methotrexate free acid and a buffer, wherein the pH of the composition is in the range of 6.5 to 8.2. Processes for preparation of the liquid pharmaceutical composition are also described. The liquid pharmaceutical composition is useful in therapy.
Inventor(s):	Michael Frodsham, Julie-Ann PENTON
Assignee:	Shorla Pharma Ltd T/a Shorla Oncology
Application Number:	US15/522,168
Patent Claims:	1. A liquid pharmaceutical composition for oral administration that is a solution comprising a combination of 0.4-20 mg/mL of methotrexate free acid; a buffer that is a citrate buffer having a buffer strength of 0.05 M; 2-6 mg/mL polyethylene glycol; 50-200 mg/mL glycerol, and one or more flavouring compounds and/or sweetening agents; wherein the pH of the solution is 6.8. 2. The composition according to claim 1, wherein the buffer is a sodium citrate buffer. 3. The composition according to claim 1, wherein the composition further comprises one or more preservatives. 4. The composition according to claim 3, wherein the one or more preservatives comprise ethyl parahydroxybenzoate and/or methyl parahydroxybenzoate. 5. The composition according to claim 4, wherein the methyl parahydroxybenzoate is methyl parahydroxybenzoate sodium salt. 6. The composition according claim 1, wherein the one or more flavouring compounds and/or sweetening agents comprise orange flavour or berry flavour and/or sucralose. 7. The composition according to claim 1, wherein the composition further comprises one or more co-solvents. 8. The composition according to claim 1, wherein the composition further comprises glycerol. 9. The composition according to claim 1, wherein the polyethylene glycol is PEG 400. 10. The composition according to claim 1 comprising: methotrexate free acid; PEG400; ethyl parahydroxybenzoate; methyl parahydroxybenzoate sodium salt; glycerol; orange flavour; sucralose; and sodium citrate buffer. 11. The composition according to claim 2, wherein the sodium citrate buffer comprises tri-sodium citrate, citric acid, and purified water. 12. The composition according to claim 1, comprising 1 mg/mL to 10 mg/mL of methotrexate free acid. 13. The composition according to claim 1, comprising 1 mg/mL to 5 mg/mL of methotrexate free acid. 14. The composition according to claim 1, having no change in appearance or pH after storage at 40° C. for three months. 15. The composition according to claim 1, having 3.5 wt. % to 4.5 wt. % of total related substances of methotrexate free acid, after storage at about 40° C. for three months. 16. The composition according to claim 1, wherein the buffer is a sodium citrate buffer comprising tri-sodium citrate, citric acid, and purified water. 17. The composition according to claim 16, comprising 1 mg/mL to 5 mg/mL of methotrexate free acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.